NCT04394247View on ClinicalTrials.gov

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

CompletedOBSERVATIONAL
Enrollment

242

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Breast Cancer
Trial Locations (1)

94107

Syapse, San Francisco

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY